Thou­sands of com­plaints and lab records in 'bags of scrap': FDA in­spects Cipla site in In­dia

An­oth­er man­u­fac­tur­ing site be­long­ing to Cipla is un­der the FDA’s mi­cro­scope.

An FDA in­spec­tion of one of Cipla’s man­u­fac­tur­ing sites in Pi­tham­pur, In­dia un­veiled sev­er­al qual­i­ty and da­ta ob­ser­va­tions be­tween Feb.6 and Feb. 23 of this year. Ac­cord­ing to the 483 re­port, the man­u­fac­tur­ing site re­ceived over 3,000 com­plaints be­tween 2020 and 2022. The FDA’s re­port al­so stat­ed that 266 com­plaints were al­so re­ceived this year and are still un­der in­ves­ti­ga­tion.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN